Clinical trials: Androgens
Effects of the External Testosteron Intake Over the Choroids of the Patients With Androgen Deficiency
Effects of External Testosteron Intake on the Choroid: Enhance-depth Imaging Optical Coherence Tomography Study
According to the results Ciloğlu et al., CSC is related to elevated total testosterone levels. Testosterone may play a role in predisposing males to CSC.
- Trial name
- NCT04342247
- Testing
- external testosteron
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Neon Hospital
Prostate Cancer
Phase I/II Study of Hydroxychloroquine With Itraconazole With Biochemically Recurrent Prostate Cancer
Recent pre-clinical work has suggested that Itraconazole has an anti-cancer effect that works synergistically with hydroxychloroquine.
- Trial name
- HITMAN-PC (NCT03513211)
- Testing
- SUBA-itraconazole, Hydroxychloroquine
- Where
- Australia
- Volunteers
- 12 people
- Sponsor
- St Vincent's Hospital, Sydney
Breast Cancer, Arthralgia
Observational Study to Evaluate Mechanisms of Aromatase Inhibitor Associated Musculoskeletal Symptoms
Early stage hormone receptor positive breast cancer is typically treated with adjuvant endocrine therapy in order to decrease risk of breast cancer recurrence and to improve overall survival from the disease.
- Trial name
- NCT02118636
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Lynn Henry
Contraception, Hypogonadism
Oral Androgens in Man-3 (ORAL T-3) Pharmacokinetics of Oral Testosterone
The purpose of this study is to test the how the body absorbs and processes new forms of oral testosterone. Information gained during the study may help develop better forms of testosterone therapy in the future.
- Trial name
- NCT00161421
- Testing
- Oral Testosterone, Leuprolide (Lupron), Dutasteride
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University of Washington
Prostate Cancer Metastatic
ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)
This is a Phase III, international, multicentre, randomised, double-blinded placebo controlled trial, evaluating the efficacy and safety of ADT +/- darolutamide in castration-naïve de novo metastatic prostate cancer patients with…
- Trial name
- GETUG-AFU 40 (NCT04916613)
- Testing
- Darolutamide 300 mg, Androgen deprivation therapy
- Where
- 95 sites in Belgium, France and 10 more
- Volunteers
- 300 people
- Sponsor
- UNICANCER
Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma
Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer
This phase II trial studies how well testosterone (enanthate or cypionate) and olaparib work in treating patients with prostate cancer that has progressed despite hormonal therapy.
- Trial name
- NCT03516812
- Testing
- Laboratory Biomarker Analysis, Olaparib, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of Washington
Prostate Cancer
Darolutamide + Androgen Deprivation Therapy (ADT) in Chinese Men With High Risk, Nonmetastatic Prostate Cancer
Researchers are seeking better ways to treat men who have non-metastatic castration resistant prostate cancer (nmCRPC). This type of prostate cancer-nmCRPC- is one that has not spread to other parts of the body yet keeps…
- Trial name
- NCT05171387
- Testing
- Darolutamide 600 mg twice daily, Androgen deprivation therapy (ADT)
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Bayer
ER+ and AR+ Breast Cancer
Efficacy and Safety of GTx-024 in Patients With Estrogen Receptor (ER)+/Androgen Receptor (AR)+ Breast Cancer
The purpose of this study is to determine if GTx-024 at different dosages (9 mg or 18 mg) is effective and safe in the treatment of patients with metastatic or locally advanced Estrogen Receptor (ER)+ and Androgen Receptor (AR)+…
- Trial name
- NCT02463032
- Testing
- GTx-024
- Where
- 4 sites in United States
- Volunteers
- 136 people
- Sponsor
- GTx
Recurrent Prostate Cancer
Effects of Muscadine Grape Extract in Men With Prostate Cancer on Androgen Deprivation Therapy
It is estimated that one-third of the more than 7 million deaths from cancer worldwide are attributable to potentially modifiable risk factors, with 374,000 deaths preventable through diet modification alone.
- Trial name
- NCT03496805
- Testing
- MGE, ADT
- Where
- 2 sites in United States
- Volunteers
- 106 people
- Sponsor
- Wake Forest University Health Sciences
Healthy
PROS-2 Dose Response Effects of Exogenous Testosterone on the Prostate
The investigators will conduct a three-month, randomized, placebo-controlled trial comparing the effects of increasing doses of androgen supplementation with Testosterone (T) gel on the prostate in healthy men who are treated…
- Trial name
- PROS-2 (NCT01327495)
- Testing
- Testosterone 1% gel 1.25 g, Testosterone 1% gel 2.5 g, Testosterone 1% gel 5.0 g
- Where
- United States
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- University of Washington
Prostatic Neoplasms, Exercise
Health Effects of Soccer Training in Men With Prostate Cancer Receiving Androgen Deprivation Therapy
Androgen Deprivation Therapy (ADT) is standard treatment for locally advanced or advanced Prostate Cancer (PC). The musculoskeletal toxicity associated with ADT is well established, leading to a decrease in muscle mass, increased…
- Conditions
- Prostatic Neoplasms, Exercise, Soccer Training, Androgen Deprivation Therapy
- Trial name
- NCT01711892
- Testing
- Soccer training
- Where
- Denmark
- Volunteers
- 57 people
- Sponsor
- University of Copenhagen
Prostate Cancer Metastatic, Hormone Refractory Prostate Cancer
Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer
The purpose of this study was to evaluate the impact of concurrent versus sequential administration of abiraterone acetate plus prednisone on the ability to manufacture sipuleucel-T (by assessing sipuleucel-T product parameters)…
- Conditions
- Prostate Cancer Metastatic, Hormone Refractory Prostate Cancer, Castration-resistant Prostate Cancer
- Trial name
- NCT01487863
- Testing
- sipuleucel-T, abiraterone acetate
- Where
- 21 sites in United States
- Volunteers
- 69 people
- Sponsor
- Dendreon
Prostate Cancer
A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy
Participants who completed the FE200486 CS21 study (NCT00295750) could enter the FE200486 CS21A study. The study continued until all non-discontinued participants had received treatment for at least 5 years.
- Trial name
- NCT00451958
- Testing
- Degarelix 80 mg / Degarelix 80 mg, Degarelix 160 mg / Degarelix 160 mg, Leuprolide 7.5 mg / Degarelix 80 mg
- Where
- 69 sites in United States, Canada and 10 more
- Volunteers
- 386 people
- Sponsor
- Ferring Pharmaceuticals
Prostate Cancer
The Effect of Endurance Training on Body Composition and Insulin Sensitivity in Prostate Cancer Patients Receiving Androgen Deprivation Therapy
The purpose of the present study is to investigate if endurance training can be used as a therapeutic action against the adverse metabolic disturbances and unfavourable changes in body composition that accompany the androgen…
- Trial name
- NCT01676480
- Testing
- Endurance training
- Where
- Denmark
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Inge Holm
Patients With High-risk Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
A Trial of SHR3680 in Prostate Cancer Patients Who Are Candidates for Radical Prostatectomy
The study is being conducted to evaluate the efficacy and safety of SHR3680 plus androgen deprivation therapy (ADT) vs. placebo plus ADT in patients with high-risk localized or locally advanced prostate cancer using pathologic…
- Trial name
- NCT05009290
- Testing
- SHR3680
- Where
- China
- Volunteers
- 391 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Advanced Solid Tumours With Androgen Receptor Pathway as a Potential Factor
Phase I Open Label Dose Escalation Study to Investigate the Safety & Pharmacokinetics of AZD5312 in Patients With Androgen Receptor Tumors
This is a first time in man (FTIM), Phase I study to determine the Maximum Tolerated Dose, Recommended Phase 2 Dose, safety, tolerability and Pharmacokinetics of AZD5312.
- Trial name
- NCT02144051
- Testing
- AZD5312
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 32 people
- Sponsor
- AstraZeneca
Prostate Cancer, Supportive Care
Behavioral Exercise Training to Reduce Cardiovascular Disease Risk
To test the preliminary effectiveness of a home-based exercise training (ET) intervention to improve exercise capacity (VO2 peak \& 6-minute walk distance [6MWD]) among prostate cancer (PC) patients compared to controls receiving…
- Trial name
- EXTRA-PC (NCT06237179)
- Testing
- Exercise Training Intervention, Healthy Living Education
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Virginia Commonwealth University
Stage IV Prostate Cancer, Adenocarcinoma of the Prostate
Docetaxel With or Without Thalidomide in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Thalidomide may stop the growth of prostate cancer by stopping blood flow to the tumor.
- Conditions
- Stage IV Prostate Cancer, Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
- Trial name
- NCT00020046
- Testing
- docetaxel, thalidomide
- Where
- United States
- Sponsor
- National Institutes of Health Clinical Center (CC)
Healthy Men, Male Contraception
Phase 1 Study of Dimethandrolone Undecanoate in Healthy Men
The long term objective is to develop a new male hormone Dimethandrolone Undecanoate (DMAU) as a male hormonal contraceptive. The study has two parts.
- Trial name
- DMAUPhase1 (NCT01382069)
- Testing
- Dimethandrolone Undecanoate
- Where
- 2 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Prostate Cancer
ASCVD Management Using CCTA in Prostate Cancer Patients on ADT
This is a randomized pilot study of Coronary CT Angiography (CCTA) for coronary atherosclerosis vs. Usual Care in patients with prostate cancer who are either planning to begin, or are currently taking androgen deprivation…
- Trial name
- NCT05879913
- Testing
- Coronary CT Angiography (CCTA)
- Where
- 3 sites in United States
- Volunteers
- 100 people
- Sponsor
- Indiana University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.